Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Elacestrant synthesis route uspto?

See the DrugPatentWatch profile for Elacestrant

What USPTO documents are likely about elacestrant synthesis?

If you’re trying to find the “elacestrant synthesis route” through USPTO, the most useful search targets are patents and applications that mention elacestrant (also spelled/treated in records as “Elacestrant” or by code names tied to the same molecule) and include language like “preparation,” “process,” “intermediate,” “manufacture,” “example,” “preparing,” or “synthetic route.”

In practice, USPTO records often show the route indirectly through:
- “Example” procedures for making elacestrant or key intermediates (with step-by-step conditions)
- Claims covering process steps (what reagent is used, order of steps, temperature/solvent ranges)
- Filing families that include multiple jurisdictions, where USPTO publishes the same core chemistry

How to search USPTO effectively for an elacestrant synthesis/process patent

The USPTO search approach usually works best if you combine the molecule name with process terms and (optionally) known chemistry descriptors.

Typical query strategies in USPTO search tools:
- Search the title/abstract/full text for “elacestrant” plus process language like “preparation” or “process for preparing”
- Add “intermediate” to narrow to documents that publish the steps used to reach the drug substance
- If you know any intermediate name or scaffold keyword used in known syntheses, include it to find the exact route
- Filter by publication type (granted patents vs published applications) depending on whether you want the final claims or the earliest disclosure

Why you may not find a “single synthesis route” in USPTO

USPTO disclosures can differ from what people mean by “synthesis route”:
- Many patents focus on specific intermediates, not the entire step-by-step route to final API.
- Process patents might describe improvements (yield, purification, safety) over an earlier route rather than reprinting a full original synthesis.
- Some disclosures are redacted at the level of exact details, or focus on scale-up/purification rather than full mechanistic steps.

So you may need to piece together multiple related documents (same patent family or continuation/divisional filings) to reconstruct a complete route.

Are there multiple “routes” (and multiple patents) for elacestrant?

Yes—drug substances often have:
- Early discovery routes disclosed in early filings
- Later process-development routes with optimized steps, catalysts, or purification steps
- Separate patents on salt forms, polymorphs, or crystallization that also change the effective “route” for manufacturing the final drug substance

That means the USPTO corpus can contain several distinct process descriptions even when they all end at the same final API.

What I need from you to give a precise USPTO “route” answer

I can’t accurately point to the exact USPTO synthesis route without at least one of the following:
- A USPTO patent/application number (or publication number, like US##########A1), or
- The assignee/company name (common for elacestrant manufacturing/process families), or
- The exact wording you’re seeing (for example, an intermediate name or a claim snippet)

Share any identifier you have (even partial), and I’ll tell you which USPTO document(s) contain the step-by-step preparation/process examples and how they map to the synthesis route.

Quick check: are you searching for “elacestrant” or a different spelling/compound?

USPTO searches are sensitive to naming. Confirm the drug name is exactly “elacestrant,” not a related compound or code name. If you have the chemical name (IUPAC) or internal code from a paper or filing, paste that too.



Other Questions About Elacestrant :

How does elacestrant treat breast cancer?